Home » Stocks » ABIO

ARCA biopharma, Inc. (ABIO)

Stock Price: $3.28 USD 0.24 (7.73%)
Updated Jul 29, 2021 11:22 AM EDT - Market open
Market Cap 44.38M
Revenue (ttm) n/a
Net Income (ttm) -12.52M
Shares Out 12.36M
EPS (ttm) -1.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $3.28
Previous Close $3.04
Change ($) 0.24
Change (%) 7.73%
Day's Open 3.10
Day's Range 3.08 - 3.41
Day's Volume 610,707
52-Week Range 2.72 - 7.38

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

WESTMINSTER, Colo., July 13, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies...

2 weeks ago - GlobeNewsWire

WESTMINSTER, Colo., July 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies...

2 weeks ago - GlobeNewsWire

Are these Reddit penny stocks the best 7 to watch in July 2021? The post Best Reddit Penny Stocks to Buy Now?

Other stocks mentioned: BDSI, DARE, GMVD, JAGX, LKCO, XELA
3 weeks ago - PennyStocks

WESTMINSTER, Colo., May 11, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies ...

2 months ago - GlobeNewsWire

WESTMINSTER, Colo., May 05, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies ...

2 months ago - GlobeNewsWire

WESTMINSTER, Colo., May 03, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies ...

2 months ago - GlobeNewsWire

WESTMINSTER, Colo., March 18, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapie...

4 months ago - GlobeNewsWire

There are some investors who purchase stocks that are trading below their liquidation value because they believe they can make impressive gains out of their investments after the market has reassessed t...

Other stocks mentioned: ATHA, MTCR
5 months ago - GuruFocus

WESTMINSTER, Colo., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that its 2020 Annual Meeting of Stockholders, scheduled for Thursday, December 10, 2020 at 9:00...

7 months ago - GlobeNewsWire

Shares of ARCA Biopharma Inc. gained 5.5% in trading on Monday after the company said it received a Fast-Track designation from the Food and Drug Administration for its mid-stage experimental COVID-19 t...

8 months ago - Market Watch

WESTMINSTER, Colo., Nov. 23, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies...

8 months ago - GlobeNewsWire

WESTMINSTER, Colo., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies...

8 months ago - GlobeNewsWire

WESTMINSTER, Colo., Oct. 07, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies...

9 months ago - GlobeNewsWire

WESTMINSTER, Colo., Oct. 05, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies...

9 months ago - GlobeNewsWire

WESTMINSTER, Colo., Sept. 21, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therap...

10 months ago - GlobeNewsWire

WESTMINSTER, Colo., Aug. 05, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapi...

11 months ago - GlobeNewsWire

WESTMINSTER, Colo., June 03, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically target...

1 year ago - GlobeNewsWire

WESTMINSTER, Colo., June 01, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically target...

1 year ago - GlobeNewsWire

Shares of Arca Biopharma tripled in value Thursday after the biotech company announced it would develop a coronavirus treatment for patients with abnormal blood clotting. The post Arca Biopharma Stock T...

1 year ago - Investors Business Daily

Arca Biopharma Inc (NASDAQ: ABIO) shares are skyrocketing toward their highest level in more than a year following an announcement from the company regarding its plan to develop a COVID-19 treatment.

1 year ago - Benzinga

WESTMINSTER, Colo., May 28, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced a new development program to evaluate AB201 (rNAPc2), a potent, selective inhibitor of tissue f...

1 year ago - GlobeNewsWire

New data provide additional evidence of efficacy for Gencaro compared to active control in a pharmacogenetically-defined HF population at risk for AF recurrence

1 year ago - GlobeNewsWire

WESTMINSTER, Colo., May 06, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapie...

1 year ago - GlobeNewsWire

WESTMINSTER, Colo., Sept. 11, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therap...

1 year ago - GlobeNewsWire

ARCA biopharma published positive results from its phase 2b GENETIC-AF study using Gencaro to treat patients with genetically-defined heart failure with atrial fibrillation.

2 years ago - Seeking Alpha

Pharma CEO defends 400% price hike as moral requirement

YouTube video

The "Squawk Box" news team discusses some of the morning's most provocative headlines.

Other stocks mentioned: JWN
2 years ago - CNBC Television

About ABIO

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase 2 clinical trial for the treatment of diseases caused by ribonucleic acid viruses initially focusing on COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase 2 trial for the treatment of atrial ... [Read more...]

Industry
Biotechnology
CEO
Michael Bristow
Employees
11
Stock Exchange
NASDAQ
Ticker Symbol
ABIO
Full Company Profile

Financial Performance

Financial Statements